Is there a potential dual effect of denosumab for treatment of osteoporosis and sarcopenia?
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Is there a potential dual effect of denosumab for treatment of osteoporosis and sarcopenia?
Authors
Keywords
-
Journal
CLINICAL RHEUMATOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-05-19
DOI
10.1007/s10067-021-05757-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Osteosarcopenia: epidemiology, diagnosis, and treatment—facts and numbers
- (2020) Ben Kirk et al. Journal of Cachexia Sarcopenia and Muscle
- Osteosarcopenia: where osteoporosis and sarcopenia collide
- (2020) Michael A Clynes et al. RHEUMATOLOGY
- Effect of Denosumab on Falls, Muscle Strength, and Function in Community‐Dwelling Older Adults
- (2019) Steven Phu et al. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
- Bone Mineral Density Changes After 1 Year of Denosumab Discontinuation in Postmenopausal Women with Long-Term Denosumab Treatment for Osteoporosis
- (2018) Albrecht Werner Popp et al. CALCIFIED TISSUE INTERNATIONAL
- Genetic deletion of muscle RANK or selective inhibition of RANKL is not as effective as full-length OPG-fc in mitigating muscular dystrophy
- (2018) Sébastien S. Dufresne et al. Acta Neuropathologica Communications
- OUP accepted manuscript
- (2018) AGE AND AGEING
- Osteosarcopenia: where bone, muscle, and fat collide
- (2017) H. P. Hirschfeld et al. OSTEOPOROSIS INTERNATIONAL
- Differentiating Sarcopenia and Cachexia Among Patients With Cancer
- (2016) Sarah J. Peterson et al. NUTRITION IN CLINICAL PRACTICE
- Osteoprotegerin Protects against Muscular Dystrophy
- (2015) Sébastien S. Dufresne et al. AMERICAN JOURNAL OF PATHOLOGY
- Use of alfacalcidol in osteoporotic patients with low muscle mass might increase muscle mass: An investigation using a patient database
- (2014) Sadayuki Ito et al. Geriatrics & Gerontology International
- Differential impact of the Bisphosphonate Alendronate on undifferentiated and terminally differentiated human myogenic cells
- (2013) Kosuke Shiomi et al. JOURNAL OF PHARMACY AND PHARMACOLOGY
- Concomitant increase in muscle strength and bone mineral density with decreasing IL-6 levels after combination therapy with alendronate and calcitriol in postmenopausal women
- (2013) Joo Hyun Park et al. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY
- Osteoporosis in the European Union: medical management, epidemiology and economic burden
- (2013) E. Hernlund et al. Archives of Osteoporosis
- Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
- (2012) Allan Lipton et al. EUROPEAN JOURNAL OF CANCER
- Is vitamin D a determinant of muscle mass and strength?
- (2011) Isabel Marantes et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Alendronate improves QOL of postmenopausal women with osteoporosis
- (2010) Hisaya Kawate Clinical Interventions in Aging
- Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy
- (2009) David L Kendler et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
- (2009) Steven R. Cummings et al. NEW ENGLAND JOURNAL OF MEDICINE
- RANKL Inhibition with Osteoprotegerin Increases Bone Strength by Improving Cortical and Trabecular bone Architecture in Ovariectomized Rats
- (2008) Michael S Ominsky et al. JOURNAL OF BONE AND MINERAL RESEARCH
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started